New Delhi: London-based SPG Media, publishers of the annual "World Pharmaceutical Frontiers" survey, has included five Indians among the top 40 influential people in the global pharmaceutical industry in 2008.
These include former drugs controller M. Venkateshwarlu, Ranbaxy CMD Malvinder Mohan Singh, Ranjit Shahani, India chief of Swiss pharma major Novartis AG, Ramaprasad Reddy, chairman Aurobindo Pharma and Rajesh Jain, joint managing director, Panacea Biotec.
The survey, which focused on "innovation" rather than "business volume", selected Mario R Capecchi, Oliver Smithie and Martin J Evans, joint winners of the 2007 Nobel Prize in Physiology or Medicine as the most influential people.
Arthur Levinson, Chairman and CEO Genetech, Bill and Melinda Gates, co-directors of Bill and Melinda Gates Foundation, Margaret Chan, director general WHO, Michael Rawlins, chairman, NICE, Andrew Witty, incoming CEO, GlaxoSmithKline, Bill Clinton, founder Clinton Foundation were among the people figured among the top 10.
Venkateshwarlu is in the 16th position, followed by Malvinder Singh at the 21 slot. Ranjit Shahani was ranked 24, up by 14 places from 38 last year. Both Ramaprasad Reddy and Rajesh Jain, at 35th and 40th positions respectively, have made the list for the first time.
"Last year, our list was dominated by business and big spenders. This year, however, there has been a shift of power, with no sign of any ‘big pharma' in the top ten. The exception is the incoming CEO of GlaxoSmithKline Andrew Witty, who has been a driving force within the organisation for years," Andrew Tunnicliffe, editor World Pharmaceutical Frontiers stated.
Other inclusions show how regulatory and governing bodies have made an impact. Michael Rawlins, NICE chairman, made it to the top five, demonstrating how the power base has shifted from pharma to those who monitor them.
The reason for this refocus from finances to innovation is, in part, the result of a tightening marketplace, fiercer competition and the opening up of the increasingly dynamic emerging economies of India and China", Andrew Tunnicliffe, editor World Pharmaceutical Frontiers stated.
In addition to Tunnicliffe, the selection panel included Agnes S. Klein, director of the Centre for Evaluation of Radiopharmaceuticals and Biotherapeutic Products in Biologics and Genetic Therapies Directorate, Clive Savage, director of Corporate Communication, IMS Health, Michael A Santoro, associate professor, Rutgers Business School, Newark, US, and Andrew Jack, pharmaceutical correspondent with Financial Times, London.
This is the second survey conducted by SPG media.
Source: Business Standard
Thursday, December 18, 2008
KAMAL NATH ADDRESSES INTERNATIONAL CONFERENCE ON PHARMA
INDIAN PHARMA COMPANIES FULLY EQUIPPED FOR NEW PATENT REGIME, SAYS KAMAL NATH ADDRESSES INTERNATIONAL CONFERENCE ON PHARMA
Date : 01 Feb 2005
Location : New Delhi
Shri Kamal Nath, Union Minister of Commerce & Industry, has said that the Indian pharmaceutical companies are poised and fully equipped to take advantage of the US $ 50 billion worth of drugs going off patent in the next five years after introduction of the new patent regime. "We’ll grab a major share of this", he said in his address at an international conference organised by the Royal Institute of International Affairs at Chatham House, London, last evening. The theme of the Conference was the pharmaceutical industry in the 21st century and whether India is challenging the conventional R&D business model.
Shri Kamal Nath told the large gathering that India presented an ideal confluence of five factors viz., (1) cost-effective manufacturing; (2) well-developed chemical industry infrastructure; (3) strong vertical integration (from bulk to formulations to packing); (4) abundant scientific talent & technical skills; and (5) unique synergy in fields of IT, biotech & medicine. "Time is, therefore, ripe for a quantum leap. Our objective is not only to manufacture drugs, but also to make India a hub for medical research and clinical data management", the Minister said.
The pharma industry in India is a $ 10 billion industry. India has 300 pharma companies of large and moderate size and another 10,000 small and tiny firms. But 70% of the production is by the top 100 larger companies. The industry manufactures about 400 bulk drugs and almost the entire range of formulations. About a third of India’s production – close to US $ 3.5 billion – is exported and exports are growing at 25% per annum. Half a billion dollars worth of exports are to the US alone, while Germany, Russia, the UK, Canada, Italy and Japan are among others. Large quantities of medicines are also exported from India to China, Brazil, Nigeria and Mexico, Shri Kamal Nath informed the large audience. But he also pointed out that: "While the statistics do reveal that India has a huge drug industry (8% of the world’s drugs are manufactured in India) – it also becomes apparent that the financial realisations are not commensurate with the size. This means that while we are getting paid for the actual stuff, there is no financial realisation for the ‘intellectual property’ value behind the formulations – and in the drug industry it is this intellectual property value that constitutes the huge margins".
"In the 21st century, the pharmaceutical value chain would depend on the ability of pharmaceutical companies to make the technological shift necessary to maintain their competitive positions. India provides not just the possibility – but the unique & tangible opportunity for international pharma firms to make that desired ‘technological shift’ – in process, and (more literally) in location! The question before Pharma Company CEOs the world over today is not: ‘Should my company go to India?’ but ‘Can my company afford not to go to India’?", Shri Kamal Nath said.
Date : 01 Feb 2005
Location : New Delhi
Shri Kamal Nath, Union Minister of Commerce & Industry, has said that the Indian pharmaceutical companies are poised and fully equipped to take advantage of the US $ 50 billion worth of drugs going off patent in the next five years after introduction of the new patent regime. "We’ll grab a major share of this", he said in his address at an international conference organised by the Royal Institute of International Affairs at Chatham House, London, last evening. The theme of the Conference was the pharmaceutical industry in the 21st century and whether India is challenging the conventional R&D business model.
Shri Kamal Nath told the large gathering that India presented an ideal confluence of five factors viz., (1) cost-effective manufacturing; (2) well-developed chemical industry infrastructure; (3) strong vertical integration (from bulk to formulations to packing); (4) abundant scientific talent & technical skills; and (5) unique synergy in fields of IT, biotech & medicine. "Time is, therefore, ripe for a quantum leap. Our objective is not only to manufacture drugs, but also to make India a hub for medical research and clinical data management", the Minister said.
The pharma industry in India is a $ 10 billion industry. India has 300 pharma companies of large and moderate size and another 10,000 small and tiny firms. But 70% of the production is by the top 100 larger companies. The industry manufactures about 400 bulk drugs and almost the entire range of formulations. About a third of India’s production – close to US $ 3.5 billion – is exported and exports are growing at 25% per annum. Half a billion dollars worth of exports are to the US alone, while Germany, Russia, the UK, Canada, Italy and Japan are among others. Large quantities of medicines are also exported from India to China, Brazil, Nigeria and Mexico, Shri Kamal Nath informed the large audience. But he also pointed out that: "While the statistics do reveal that India has a huge drug industry (8% of the world’s drugs are manufactured in India) – it also becomes apparent that the financial realisations are not commensurate with the size. This means that while we are getting paid for the actual stuff, there is no financial realisation for the ‘intellectual property’ value behind the formulations – and in the drug industry it is this intellectual property value that constitutes the huge margins".
"In the 21st century, the pharmaceutical value chain would depend on the ability of pharmaceutical companies to make the technological shift necessary to maintain their competitive positions. India provides not just the possibility – but the unique & tangible opportunity for international pharma firms to make that desired ‘technological shift’ – in process, and (more literally) in location! The question before Pharma Company CEOs the world over today is not: ‘Should my company go to India?’ but ‘Can my company afford not to go to India’?", Shri Kamal Nath said.
Subscribe to:
Posts (Atom)